Isis and Sanofi's Drug OK'd to Treat Inherited Cholesterol Disease
Isis Pharmaceuticals (NASDAQ:ISIS) and Sanofi (NYSE:SNY) won US approval to sell the drug Kynamro for a rare inherited condition that raises bad cholesterol and can cause heart disease in young people. Sanofi’s Genzyme will sell the drug under a licensing agreement. Isis will receive a $25 million milestone payment for getting market clearance from the US Food and Drug Administration. Shares of Isis rose 8% to $14.49 in pre-market trading Wednesday morning. The shares have climbed more than 50% in the past three months. Paris-based Sanofi’s US shares rose 1% to $49.35. That stock is up 11% in the ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here